Get the Stockscreener App
1.14
8.80%
-0.11
After Hours:
1.14
Telomir Pharmaceuticals Inc stock is traded at $1.14, with a volume of 125.02K.
It is down -8.80% in the last 24 hours and down -10.24% over the past month.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
See More
Previous Close:
$1.25
Open:
$1.24
24h Volume:
125.02K
Relative Volume:
0.96
Market Cap:
$39.19M
Revenue:
-
Net Income/Loss:
$-10.41M
P/E Ratio:
-3.3918
EPS:
-0.3361
Net Cash Flow:
$-3.69M
1W Performance:
-10.94%
1M Performance:
-10.24%
6M Performance:
-14.93%
1Y Performance:
-71.14%
1-Day Range:
$1.10
$1.255
1-Week Range:
$1.10
$1.33
52-Week Range:
$1.05
$4.005
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.14 | 42.98M | 0 | -10.41M | -3.69M | -0.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today
Telomir Shareholders Approve Equity Plan and Bylaw Changes - TipRanks
Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union
Telomir Pharmaceuticals shareholders approve acquisition and bylaw changes - Investing.com UK
Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - Stock Titan
Pharma News: Should I trade or invest in Telomir Pharmaceuticals Inc2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Setup Watch: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn
Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart
Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn
Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) details 2025 results, Telomir-1 plans and TELI merger - Stock Titan
US Market Recap: Will Unisys Corporation stock go up in YEAR2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Telomir Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Winners Losers: Is Telomir Pharmaceuticals Inc a top pick in the sectorTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Risk Analysis: Can Genco Shipping Trading Limited be recession proofWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Action: Is Telomir Pharmaceuticals Inc. a good ESG investmentQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Portfolio Recap: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Nasdaq Moves: Is Telomir Pharmaceuticals Inc a good ESG investment2025 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire
TELO Technical Analysis & ETF Price Forecast - Intellectia AI
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Activity Recap: Is Telomir Pharmaceuticals Inc stock influenced by commodity pricesCPI Data & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Valuation Update: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Selloffs & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines () - aktiencheck.de
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Telomir Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell? - Defense World
Telomir Sets Vote on Transformative TELI Merger and Governance Changes - The Globe and Mail
Telomir reveals promising preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals demonstrates broad tumor cell mortality in human triple-negative breast cancer models - marketscreener.com
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models. - Bitget
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - marketscreener.com
Telomir (NASDAQ: TELO) posts new Telomir-1 preclinical data in triple-negative breast cancer - Stock Titan
Experimental breast cancer drug triggers iron-dependent tumor cell death - Stock Titan
Investment Report: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
What are the risks of holding Telomir Pharmaceuticals Inc.Trade Exit Summary & Entry Point Confirmation Signals - mfd.ru
Is Telomir Pharmaceuticals Inc. a top pick in the sectorTrade Signal Summary & Weekly Momentum Picks - mfd.ru
Will Telomir Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Growth Report & Community Supported Trade Ideas - mfd.ru
John Paul DeJoria holds 9.4% of Telomir (TELO) common stock - Stock Titan
Can Telomir Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Sentiment & Precise Swing Trade Alerts - mfd.ru
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - ACCESS Newswire
What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks
Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - Stock Titan
Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView
Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):